Scarica l'app Stockscreener
2.97
4.58%
0.13
Dopo l'orario di chiusura:
2.96
-0.01
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.84
Aprire:
$2.84
Volume 24 ore:
6.29M
Relative Volume:
0.96
Capitalizzazione di mercato:
$598.82M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.4009
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+9.59%
1M Prestazione:
+12.08%
6M Prestazione:
+197.18%
1 anno Prestazione:
+45.59%
Intervallo 1D:
$2.80
$3.01
Intervallo di 1 settimana:
$2.73
$3.11
Portata 52W:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.97 | 657.81M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Why analysts remain bullish on Esperion Therapeutics Inc. stockWeekly Loss Report & Real-Time Volume Analysis - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.July 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
Should you wait for a breakout in Esperion Therapeutics Inc.Trade Risk Assessment & Smart Allocation Stock Tips - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fake2025 Market WrapUp & Accurate Buy Signal Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.July 2025 Drop Watch & Growth Focused Stock Reports - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflationJuly 2025 Weekly Recap & Fast Exit and Entry Strategy Plans - newser.com
Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Thursday - MarketBeat
Why Esperion Therapeutics Inc. stock is favored by top institutions2025 Analyst Calls & Smart Allocation Stock Reports - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beat2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Why Esperion Therapeutics Inc. is moving todayLong Setup & Risk Controlled Swing Alerts - newser.com
Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.Weekly Trade Recap & Weekly Breakout Watchlists - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockMarket Activity Report & Free Technical Confirmation Trade Alerts - newser.com
Relative strength of Esperion Therapeutics Inc. in sector analysisEarnings Growth Report & Risk Controlled Daily Plans - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price action2025 Market Trends & Technical Buy Zone Confirmation - newser.com
How to use Fibonacci retracement on Esperion Therapeutics Inc.Portfolio Performance Report & AI Enhanced Trade Execution Alerts - newser.com
Using AI based signals to follow Esperion Therapeutics Inc.Portfolio Growth Summary & Fast Gaining Stock Strategy Reports - newser.com
How high can Esperion Therapeutics Inc. stock go2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - newser.com
Published on: 2025-10-30 01:22:55 - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.Quarterly Trade Summary & Low Drawdown Trading Strategies - newser.com
Applying Elliott Wave Theory to Esperion Therapeutics Inc.Quarterly Market Review & Community Consensus Trade Signals - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Trading 7.1% HigherTime to Buy? - MarketBeat
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsWeekly Volume Report & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-10-28 23:56:41 - newser.com
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. - The Manila Times
How Esperion Therapeutics Inc. stock benefits from global expansion2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Esperion (NASDAQ: ESPR) sets Nov. 11, 2 p.m. ET KOL webinar on statin intolerance - Stock Titan
Will Esperion Therapeutics Inc. stock return to pre crisis levelsWeekly Gains Summary & High Conviction Buy Zone Picks - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price targetPortfolio Risk Summary & Technical Pattern Alert System - newser.com
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Esperion Therapeutics Inc Azioni (ESPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Looker Benjamin | General Counsel |
Sep 17 '25 |
Sale |
2.80 |
6,267 |
17,573 |
393,670 |
| Koenig Sheldon L. | President and CEO |
Sep 17 '25 |
Sale |
2.79 |
28,427 |
79,254 |
1,518,831 |
| Halladay Benjamin | Chief Financial Officer |
Sep 17 '25 |
Sale |
2.81 |
7,046 |
19,785 |
474,862 |
3.18%
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):